Show simple item record

Oral Tau Aggregation Inhibitor for Alzheimer’s Disease : Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate

dc.contributor.authorWischik, Claude M.
dc.contributor.authorBentham, P.
dc.contributor.authorGauthier, S.
dc.contributor.authorMiller, S.
dc.contributor.authorKook, K.
dc.contributor.authorSchelter, B. O.
dc.date.accessioned2022-11-19T00:08:38Z
dc.date.available2022-11-19T00:08:38Z
dc.date.issued2022-10
dc.identifier218582277
dc.identifierf0f1f406-c25a-496e-a7f3-7080cabd31c6
dc.identifier85132707248
dc.identifier000815429600001
dc.identifier36281683
dc.identifier.citationWischik , C M , Bentham , P , Gauthier , S , Miller , S , Kook , K & Schelter , B O 2022 , ' Oral Tau Aggregation Inhibitor for Alzheimer’s Disease : Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylate ' , Journal of Prevention of Alzheimer's Disease , vol. 9 , pp. 780-790 . https://doi.org/10.14283/jpad.2022.63en
dc.identifier.issn2274-5807
dc.identifier.urihttp://aura-test.abdn.ac.uk/handle/2164/19291
dc.descriptionAcknowledgements: We gratefully acknowledge the contribution of the scientific advisory board, study investigators, and the generosity of study participants. The authors thank EVERSANA™ for providing medical writing support, which was funded by TauRx Therapeutics in accordance with Good Publication Practice (GPP3) guidelines ( http://www.ismpp.org/gpp3 ). Funding: The study was funded and sponsored by TauRx Therapeutics (Singapore). The funder of the study took the lead in designing and conducting the study, as well as writing of the report.en
dc.format.extent11
dc.format.extent1196799
dc.language.isoeng
dc.relation.ispartofJournal of Prevention of Alzheimer's Diseaseen
dc.subjectSDG 3 - Good Health and Well-beingen
dc.subjectAlzheimer’s diseaseen
dc.subjecthydromethylthionine mesylateen
dc.subjectLeuco-methylthioninium bis(hydromethanesulphonate)en
dc.subjectLMTMen
dc.subjecttau aggregation inhibitoren
dc.subjectR Medicine (General)en
dc.subjectClinical Neurologyen
dc.subjectPsychiatry and Mental healthen
dc.subject.lccR1en
dc.titleOral Tau Aggregation Inhibitor for Alzheimer’s Disease : Design, Progress and Basis for Selection of the 16 mg/day Dose in a Phase 3, Randomized, Placebo-Controlled Trial of Hydromethylthionine Mesylateen
dc.typeJournal articleen
dc.contributor.institutionUniversity of Aberdeen.Neuroscienceen
dc.contributor.institutionUniversity of Aberdeen.Applied Medicineen
dc.contributor.institutionUniversity of Aberdeen.Institute of Medical Sciencesen
dc.contributor.institutionUniversity of Aberdeen.Institute for Complex Systems and Mathematical Biology (ICSMB)en
dc.contributor.institutionUniversity of Aberdeen.Physicsen
dc.description.statusPeer revieweden
dc.identifier.doi10.14283/jpad.2022.63
dc.identifier.urlhttp://www.scopus.com/inward/record.url?scp=85132707248&partnerID=8YFLogxKen


Files in this item

Thumbnail
Name:
Szlachetka_etal_CDMCN_Should_B ...
Size:
137.2Kb
Format:
PDF
View/Open

This item appears in the following Collection(s)

Show simple item record